Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Desc)]
Φίλτρα: Συντάκτης is Karagiannis, Asterios  [Clear All Filters]
2015
Tziomalos, K., Athyros V. G., Paschos P., & Karagiannis A. (2015).  Nonalcoholic fatty liver disease and statins.. Metabolism. 64(10), 1215-23.
Kargiotis, K., Athyros V. G., Giouleme O., Katsiki N., Katsiki E., Anagnostis P., et al. (2015).  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.. World J Gastroenterol. 21(25), 7860-8.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention.. Curr Med Res Opin. 31(2), 191-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Doumas, M., Athyros V., & Karagiannis A. (2015).  Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?. Cardiology. 131(3), 186-8.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.. Expert Rev Cardiovasc Ther. 13(9), 1059-66.
2016
Athyros, V. Gabriel, Doumas M., & Karagiannis A. (2016).  Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action.. Indian Heart J. 68(5), 596-598.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2016).  Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs.. Curr Vasc Pharmacol. 14(2), 208-10.
Katsiki, N., Athyros V. G., & Karagiannis A. (2016).  Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.. Curr Vasc Pharmacol. 14(6), 523-533.
Pantelidis, P., Staikoglou N., Paparoidamis G., Drosos C., Karamaroudis S., Samara A., et al. (2016).  Medical students' satisfaction with the Applied Basic Clinical Seminar with Scenarios for Students, a novel simulation-based learning method in Greece.. J Educ Eval Health Prof. 13, 13.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Off target effects of statins shape total mortality?. J Drug Assess. 5(1), 4-5.
Boutari, C., Stavropoulos K., Imprialos K., Doumas M., & Karagiannis A. (2016).  PATHWAY-2: spironolactone for resistant hypertension.. Lancet. 387(10026), 1371-1372.
Romiopoulos, I., Pyrpasopoulou A., Varouktsi A., Simoulidou E., Kontopoulou K., Karantani E., et al. (2016).  A Rare Case of Disseminated Pyogenic Gonococcal Infection in an Immunocompetent Woman.. Case Rep Infect Dis. 2016, 9629761.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.. Curr Pharm Des. 22(18), 2723-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
Katsiki, N., Kollari E., Dardas S., Dardas P., Haidich A-B., Athyros V. G., et al. (2016).  Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study.. Open Cardiovasc Med J. 10, 64-8.
2017
Theocharidou, E., Gossios T. D., & Karagiannis A. (2017).  Acute Coronary Syndrome in Patients With Inflammatory Bowel Diseases: The Plaque and the Thrombus.. Angiology. 68(10), 843-844.
Doumas, M., Stavropoulos K. V., Boutari C., Imprialos K. P., & Karagiannis A. (2017).  Blood pressure and cardiovascular outcomes: a closer look.. Lancet. 389(10076), 1295-1296.
Athyros, V. G., Tziomalos K., Doumas M., Sfikas G., & Karagiannis A. (2017).  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.. Curr Pharm Des. 23(10), 1477-1483.
Imprialos, K. P., Stavropoulos K., Doumas M., Karagiannis A., & Athyros V. G. (2017).  The effect of SGLT2 inhibitors on cardiovascular events and renal function.. Expert Rev Clin Pharmacol. 10(11), 1251-1261.
Athyros, V. G., Papageorgiou A., Athyrou V., & Karagiannis A. (2017).  Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre. J Clin Lipidol. 11(1), 306-307.
Tsaganos, T., Tseti I. K., Tziolos N., Soumelas G-S., Koupetori M., Pyrpasopoulou A., et al. (2017).  Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection.. Br J Clin Pharmacol. 83(4), 742-750.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές